Longitudinal measurement of synaptic density to monitor progression of Parkinson's disease and Huntington's disease KU Leuven
Parkinson’s disease (PD) and Huntington’s disease (HD) are disabling neurodegenerative disorders that affect the basal ganglia and multiple other brain regions. Current therapies for both disorders are purely symptomatic. There are no biomarkers yet that objectively quantify the progression of PD and HD in their motor and non-motor domains, and this hampers the development of disease-modifying therapies that slow down PD or HD ...
Simultaneous in vivo measurement of the cerebral type 1 cannabinoid receptor and endocannabinoid levels in transgenic rats of Huntington's disease. KU Leuven
Imaging methodology for Huntington's disease. University of Antwerp
Genetics in everyday life. A qualitative study of individuals at risk of hereditary breast and ovarian cancer (BRCA) and Huntington’s disease (HD) about fears of genetic discrimination KU Leuven
For decades, as our understanding of human genetics has continued to advance, socio-ethical and legal scholars have raised questions and concerns about the ethical and social implications (ELSI issues) of genetics. One specific ELSI concern is that increased knowledge and applications of human genetics might lead to new forms of negative treatment, discrimination, and stigmatisation. In the nineties, several Western countries responded to ...